Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management | LifeSciVC
This article highlights the story of Korro Bio, a biotechnology startup in Cambridge, Massachusetts, co-founded by MBL Senior Scientist Joshua Rosenthal. His research focuses on RNA editing, which Korro aims to apply to human therapeutics.
It has been an extraordinary journey so far and one that continues to humble, inspire and motivate me every day. I’ve had the honor and responsibility of building a visi on that is ambitious while being grounded in scientific rigor. Over the last 4.5 years, Korro has been built by mitigating one layer of risk at a time. This has culminated in a strong team, a robust pipeline, a set of supportive investors, board members, and key opinion leaders.
2025 holds to be a transformative year for us, with the potential for multiple milestones to come to fruition, with the biggest value inflection being the interim clinical data from our lead asset KRRO-110, a potential best in class compound for patients with Alpha-1 antitrypsin deficiency (AATD). Read the rest of the article here.
Source: Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management | LifeSciVC